CPRX - Catalyst Pharmaceuticals' quarterly net gain narrows though revenue increases

Catalyst Pharmaceuticals (NASDAQ:CPRX) saw its Q4 2021 net income decline ~19% year over year even though revenue increased and beat estimates. Q4 net income stood at ~$9.3M ($0.09 per share, basic and diluted). Revenue increased ~24% year over year to ~$38.1M. Total operating costs and expenses in the quarter was ~$25.6M, a 14% increase compared to Q4 2020. Catalyst ended the year with $171.4M in cash. The company noted it is actively pursuing opportunities to diversify its commercial and development pipeline. Read why Seeking Alpha contributor Out of Ignorance considers Catalyst (CPRX) a hold.

For further details see:

Catalyst Pharmaceuticals' quarterly net gain narrows though revenue increases